Becton, Dickinson and Company (NYSE:BDX) Updates FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 14.750-15.050 for the period, compared to the consensus EPS estimate of 14.850. The company issued revenue guidance of -, compared to the consensus revenue estimate of $22.8 billion.

Becton, Dickinson and Company Trading Down 0.3%

BDX stock traded down $0.58 during midday trading on Friday, hitting $176.81. 1,991,171 shares of the company’s stock were exchanged, compared to its average volume of 2,448,619. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $50.68 billion, a PE ratio of 31.83, a P/E/G ratio of 1.42 and a beta of 0.25. The business has a 50-day simple moving average of $187.07 and a two-hundred day simple moving average of $182.55.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be given a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Piper Sandler decreased their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada lowered their target price on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a report on Friday. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $203.50.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 1,032 shares of company stock valued at $193,040 in the last 90 days. 0.36% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. TOMS Capital Investment Management LP acquired a new position in shares of Becton, Dickinson and Company during the second quarter worth about $69,934,000. BNP Paribas Financial Markets boosted its holdings in Becton, Dickinson and Company by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 822,694 shares of the medical instruments supplier’s stock valued at $141,709,000 after purchasing an additional 297,558 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Becton, Dickinson and Company by 27.8% in the 2nd quarter. AQR Capital Management LLC now owns 672,218 shares of the medical instruments supplier’s stock valued at $114,916,000 after buying an additional 146,386 shares during the last quarter. Man Group plc increased its position in shares of Becton, Dickinson and Company by 892.7% during the second quarter. Man Group plc now owns 127,007 shares of the medical instruments supplier’s stock worth $21,877,000 after purchasing an additional 114,213 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in Becton, Dickinson and Company by 66.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 161,946 shares of the medical instruments supplier’s stock valued at $27,895,000 after acquiring an additional 64,670 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.